Reviewer’s report

Title: Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following Percutaneous Coronary Intervention: A systematic review and meta-analysis of published Randomized Controlled Trials

Version: 0 Date: 27 Feb 2018

Reviewer: Peter Penson

Reviewer's report:
I enjoyed reading this interesting manuscript. The paper describes an important clinical question. I have the following comments.

Authorship:
The authorship of the manuscript is unclear. The title page lists one author's names, but the contributions section has more than one set of initials. The methods section appears to suggest that a single author may have conducted the searches and data extraction. I would strongly suggest that a second author checks all stages of searching, screening papers and data extraction. If this has been done already, it should be stated in the manuscript.

Language:
There are many errors in the use of English Grammar in the manuscript. Sometimes (e.g. the first paragraph of the background section) this makes it very hard to understand the flow of the argument. I would strongly suggest review of the manuscript by an English Language editing service.

Search strategy:
Please provide a separate document with the full search strategy for all databases.

Protocol Registration:
Please indicate whether the protocol for the study was prospectively registered (e.g. in the PROSPERO database)

Minor points:
You frequently refer to 'guidelines' in the text, it would be helpful at each instance to explicitly state which guidelines you are referring to.
P3 Line 24: Please clarify what is meant by 'effective cardiac outcomes'
P5 L54: The study was presumably assessed according to the criteria of the Cochrane collaboration - rather than by Cochrane as stated.
P10 L7: Please clarify what is meant by 'better outcomes'

Discussion
-Given that there was no overall effect of cilostazol on the whole population, it was perhaps ambitious to expect that you might find differences in subgroups.

**Are the methods appropriate and well described?**
If not, please specify what is required in your comments to the authors.
Yes

**Does the work include the necessary controls?**
If not, please specify which controls are required in your comments to the authors.
Yes

**Are the conclusions drawn adequately supported by the data shown?**
If not, please explain in your comments to the authors.
Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.
I am able to assess the statistics
Quality of written English

Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests

Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organisation that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I own 4 shares in AstraZeneca PLC, I have received speaker's fees from Amgen Inc.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.
I agree to the open peer review policy of the journal